Immunodiagnostic Systems strengthens endocrinology offering with Diametra buy
This article was originally published in Clinica
Immunodiagnostic Systems has acquired Italian immunoenzymatic assays specialist Diametra for an undisclosed fee, as it builds its presence in the specialty testing arena. In particular, the deal strengthens IDS’s endocrinology pipeline. Milan-based Diametra has around 25 employees, and in 2013 generated revenues of €3.3m ($4.3m) and earnings before interest and tax of €0.3m. As well as endocrinology, the company has a wide variety of tests covering areas including molecular biology, hypertension, autoimmune disease, diabetes monitoring, and tumor markers. The two firms already have a relationship, and for the past nine months have been collaborating to convert one of Diametra’s manual assays onto IDS’s fully automated IDS-iSYS instrument. IDS intends to convert several more of Diametra’s steroid hormone tests onto the IDS-iSYS. Diametra also gives IDS additional development and manufacturing capabilities.